CoC Brief
Dec. 17, 2014

Genomic health test could reduce overtreatment of breast cancer
Recently, the San Antonio Breast Cancer Symposium featured new evidence for a tool that might inform treatment decisions in women with low-grade breast tumors. Since the 1980s, diagnoses of DCIS (ductal carcinoma in situ) have risen dramatically due to enhanced screening. Questions about this condition — whether it's likely to cause harm and how to manage it — are central to debate about mammography, the concept of overdiagnosis, and overtreatment.More

Study shows numeracy linked to bowel cancer screening
People who have problems with numbers may be more likely to feel negative about bowel cancer screening, including fearing an abnormal result, while some think the test is disgusting or embarrassing, according to a Cancer Research UK-supported study published recently in the Journal of Health Psychology. The researchers sent information about bowel cancer screening to patients aged from 45 to 59 along with a questionnaire that assessed their numerical skills and attitudes to the screening test, which looks for blood in stool samples.More

UnitedHealthcare, MD Anderson deal may spur more bundled payments in cancer
Modern Healthcare
Two major players in the private sector have launched a fixed-payment structure for cancer care that could serve as a harbinger of similar arrangements as the appetite for such payment reforms continues to grow across the industry.More

Registration now open for Accreditation 101: Learning the Basics of CoC Accreditation and Standards

The Commission on Cancer (CoC), a Quality Program of the American College of Surgeons, encourages you to attend Accreditation 101: Learning the Basics of CoC Accreditation and Standards in Chicago on February 27, 2015. This program provides practical information on how to achieve compliance and discusses your role as a member of a patient-centered, multidisciplinary cancer care team. This is the only education program that is developed and taught by CoC surveyors and staff. Learn how to turn theory into reality and see how the CoC standards can be used as a guide for the development of a high-quality program that treats patients with cancer.More

Hormone-unrelated breast cancer death rate lowered by reducing dietary fat
Medical News Today
Reducing dietary fat intake for at least five years after diagnosis could help improve survival rates for early-stage breast cancer patients with hormone-unrelated breast cancer, according to a new study. The findings of the study were presented at the 2014 San Antonio Breast Cancer Symposium, a five-day conference aiming to provide state-of-the-art information on breast cancer research to an audience of researchers and physicians from more than 90 countries.More

Managing obesity should be part of cancer care
Oncology Nurse Advisor
Obesity is at an epidemic level in the United States and globally. More than two-thirds of American adults are overweight or obese. Obesity contributes to avoidable and premature deaths from the top two killers: cardiovascular disease and cancer. People who are overweight or obese have a higher risk of other serious health conditions, including type 2 diabetes and high blood pressure.More

Ottawa cancer researcher says new approach to cancer could bring cure
VideoBrief There are exciting times for cancer researchers in Canada, particularly a leading-edge team in Ottawa. They are forming a nationwide partnership, and they are talking about a cure. Ottawa's own Dr. John Bell takes the lead on this research. With $60 million dollars in funding, they are setting out to find ways that a patient's own body can help cure his or her cancer. For decades, the treatment protocol for cancer has been powerful chemotherapy drugs that are sometimes as harsh as the diagnosis itself and radiation that can leave burns and scars.More

Molecular link discovered between prostate and breast cancer suggests new treatment approach for men's tumor
Weill Cornell Medical College
Prostate cancer can be driven by the same estrogen receptor responsible for the most common form of breast cancer, Weill Cornell Medical College researchers report. Their findings suggest why the most aggressive forms of prostate cancer do not respond to traditional therapy. The study also opens up potential for new prognostic biomarkers and treatments, researchers say.More

Herceptin for HER2-positive breast cancer improves long-term survival
Medical News Today
A study that analyzed the long-term safety and effectiveness of trastuzumab — more commonly known as Herceptin — found it significantly improves long-term survival of patients with HER2-positive breast cancer when combined with chemotherapy. The study, published in the Journal of Clinical Oncology, analyzed data from two independent trials designed to examine overall survival of patients with early-stage HER2-positive breast cancer who received chemotherapy with and without Herceptin.More

Preclinical studies confirm TRXE-009 as new potential treatment for melanoma
Novogen Limited, an Australian/US biotechnology company, recently announced that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in preclinical studies also to be highly active against melanoma. The company believes this is an important breakthrough discovery for two reasons. The first is that it confirms that TRXE-009 is an important new potential treatment for melanoma, including for the treatment of secondary brain cancers due to melanoma for which there currently are no effective therapies. The second is that it offers evidence for the first time of a hypothesized link between brain cancer and melanoma.More